Tandem Diabetes Care TNDM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's cash & equivalents?
- Tandem Diabetes Care (TNDM) reported cash & equivalents of $179.33M in Q1 2026.
- How has Tandem Diabetes Care's cash & equivalents changed year-over-year?
- Tandem Diabetes Care's cash & equivalents increased by 234.7% year-over-year, from $53.57M to $179.33M.
- What is the long-term trend for Tandem Diabetes Care's cash & equivalents?
- Over 5 years (2020 to 2025), Tandem Diabetes Care's cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $94.61M to $90.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.